News
GTBP
2.750
+0.37%
0.010
Weekly Report: what happened at GTBP last week (1202-1206)?
Weekly Report · 4d ago
Weekly Report: what happened at GTBP last week (1125-1129)?
Weekly Report · 12/02 12:24
GT Biopharma Price Target Announced at $11.00/Share by Roth MKM
Dow Jones · 12/02 11:00
Roth MKM Initiates Coverage On GT Biopharma with Buy Rating, Announces Price Target of $11
Benzinga · 12/02 10:50
GT Biopharma initiated with a Buy at Roth MKM
TipRanks · 12/02 10:15
GT Biopharma Receives Nasdaq Non-Compliance Delisting Notice
Benzinga · 11/27 21:14
GT BIOPHARMA INC - RECEIVES NASDAQ DELISTING NOTICE FOR FALLING BELOW $2.5 MLN EQUITY MINIMUM
Reuters · 11/27 21:07
Weekly Report: what happened at GTBP last week (1118-1122)?
Weekly Report · 11/25 12:12
GT Biopharma Announces Partnership With University Of Minnesota For Phase 1 Clinical Trial Of GTB-3650 Tri-Specific Killer Engager For High-Risk MDS, Refractory/Relapsed AML, And Minimal Residual Disease; University To Sponsor IND Application.
Benzinga · 11/21 14:30
GT BIOPHARMA INC - THE UNIVERSITY SHALL SPONSOR AN INVESTIGATIONAL NEW DRUG APPLICATION FOR IND 165546 GTB-3650
Reuters · 11/21 14:29
GT BIOPHARMA INC - ENTERED INTO INVESTIGATOR INITIATED CLINICAL TRIAL AGREEMENT WITH REGENTS OF UNIVERSITY OF MINNESOTA
Reuters · 11/21 14:29
Weekly Report: what happened at GTBP last week (1111-1115)?
Weekly Report · 11/18 12:08
GT Biopharma GAAP EPS of -$1.53
Seeking Alpha · 11/15 09:17
*GT Biopharma: GTB-3650 TriKE Phase 1 Trial First Patient Dosed Expected in 4Q; Initial Clinical Data Expected in 2Q of 2025
Dow Jones · 11/14 21:11
*GT Biopharma: Cash of About $6.5 M as of Sept 30 Anticipated to Fund Ops Into 2Q of 2025 >GTBP
Dow Jones · 11/14 21:10
GT Biopharma Q3 EPS $(1.53) Up From $(1.77) YoY
Benzinga · 11/14 21:06
*GT Biopharma 3Q Loss/Shr $1.53 >GTBP
Dow Jones · 11/14 21:00
*GT Biopharma 3Q Loss $3.41M >GTBP
Dow Jones · 11/14 21:00
Weekly Report: what happened at GTBP last week (1104-1108)?
Weekly Report · 11/11 12:28
Weekly Report: what happened at GTBP last week (1028-1101)?
Weekly Report · 11/04 12:23
More
Webull provides a variety of real-time GTBP stock news. You can receive the latest news about Gt Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About GTBP
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. Its TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer (NK) cells. The Company is also using its TriKE platform to develop therapeutics useful for the treatment of infectious disease such as for the treatment of patients infected by the human immunodeficiency virus (HIV). Its GTB-3550 is the first-generation TriKE product candidate which was a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15, all connected by small peptide linkers.